Pharmaceutical Excipients Market: Formulation Ingredients Enabling Drug Delivery

The active ingredient in a tablet is only part of what makes a medicine work. The other 90–99% of a tablet's mass consists of excipients — inactive ingredients that bind, fill, coat, stabilise, solubilise or control the release of the active pharmaceutical ingredient (API). Without the right excipients, the API may not dissolve correctly in the body, may degrade on the shelf, may taste unacceptable, or may be impossible to manufacture at scale. The pharmaceutical excipients market produces these essential formulation ingredients — a specialised chemistry sector closely tied to pharmaceutical innovation and the growing complexity of modern drug molecules.

This article explains the main excipient categories, their functions in drug formulation, key application areas and the global market outlook.

Key Takeaways

• Oral solid dosage forms (tablets and capsules) represent the largest excipient application, accounting for the majority of excipient volume consumed globally.
• Biologics and complex drug molecules are driving demand for sophisticated excipients that can stabilise proteins and enable controlled or targeted drug delivery.
• Regulatory requirements for excipient safety and documentation are significant, with major pharmacopoeias (USP, EP, JP) defining quality standards.
• Solubilisation excipients for poorly water-soluble drugs (an increasing proportion of new chemical entities) are the fastest-growing sub-category.

Main Excipient Categories

• Fillers and diluents: provide bulk volume to tablets. Microcrystalline cellulose (MCC), lactose, dibasic calcium phosphate and mannitol are the most widely used. MCC is the dominant filler for direct compression formulations.
• Binders: hold tablet components together. PVP (polyvinylpyrrolidone), HPMC (hydroxypropyl methylcellulose), HPC and starch. Critical for granulation processes.
• Disintegrants: enable tablets to break apart rapidly in the gastrointestinal tract for drug release. Croscarmellose sodium, crospovidone and sodium starch glycolate are the major types. "Super-disintegrants" enable fast-dissolve formulations.
• Coatings: film coatings protect tablets from moisture and light, improve taste masking and control release. HPMC, ethylcellulose and acrylic polymers (Eudragit) are key coating materials. Enteric coatings protect drugs from stomach acid.
• Lubricants and glidants: improve powder flow and prevent sticking during tabletting. Magnesium stearate is the dominant lubricant; colloidal silicon dioxide is the principal glidant.
• Solubilisers: improve dissolution of poorly water-soluble APIs. Cyclodextrins, PEG, Polysorbate 80, lipid-based formulation systems and co-solvents. Increasing importance as many new drug candidates have poor solubility.
• Controlled release polymers: extend drug release over hours to reduce dosing frequency and improve patient compliance. HPMC matrix tablets, ethylcellulose membrane coatings and acrylic polymers.
• Injectable excipients: tonicity agents, pH buffers, preservatives and stabilisers for parenteral formulations. Critical for protein biologic stability.

Market Context

The global pharmaceutical excipients market is valued in the billions of dollars annually and growing steadily, closely tracking pharmaceutical industry R&D and manufacturing activity. See Actual Market Research's report on the global pharmaceutical excipients market for detailed analysis. Major suppliers include DFE Pharma, Roquette, Ashland (now Ashland Specialty Ingredients), BASF Pharma, DowDuPont (now Dow and DuPont), JRS Pharma and Lubrizol. For related drug delivery context, see our guide to the drug delivery systems market.

Biologics: The Innovation Challenge

The shift toward protein biologics (monoclonal antibodies, enzymes, peptides) as therapies creates significant formulation challenges that commodity excipients cannot always meet. Protein drugs are inherently unstable — they can aggregate, denature or oxidise during processing, storage or administration, losing efficacy and potentially causing immunogenic reactions. Formulating stable biologics requires:

• Cryoprotectants for lyophilised (freeze-dried) formulations (sucrose, trehalose).
• Surfactants to prevent protein adsorption to surfaces and interfaces (Polysorbate 20 and 80).
• Amino acids and sugars as stabilisers and tonicity agents.
• High-concentration formulation for subcutaneous self-injection — requiring viscosity-reducing excipients and specialised delivery devices.

Solubility Enhancement

A large proportion of new drug candidates — estimated at 40–90% depending on the classification — have poor water solubility, limiting their oral bioavailability. Pharmaceutical excipients play a central role in solubility enhancement strategies including:

• Solid dispersion using amorphous polymer matrices (HPMC-AS, PVP-VA) to improve dissolution.
• Cyclodextrin complexation to encapsulate hydrophobic drug molecules and improve water solubility.
• Lipid-based drug delivery systems (LBDDS) including self-emulsifying formulations.
• Nanoparticle formulations with excipients that stabilise drug nanocrystals or nanosuspensions.

Regulatory Considerations

Pharmaceutical excipients must comply with monograph requirements in major pharmacopoeias (USP, European Pharmacopoeia, Japanese Pharmacopoeia). Changes to excipients in approved drug products may require regulatory submissions. Excipient manufacturers increasingly use pharmaceutical quality management systems (similar to drug manufacturers) to support customer regulatory requirements. The IPEC (International Pharmaceutical Excipients Council) has developed voluntary guidelines for excipient safety and quality.

Regional Outlook

North America and Europe account for the largest pharmaceutical excipient consumption, tied to the major pharmaceutical manufacturing hubs. Asia-Pacific, particularly India and China, is the fastest-growing region as pharmaceutical manufacturing capacity expands. India is both a large consumer (as the world's largest generics manufacturer) and a growing producer of excipients.

Technology Trends

• Novel excipients co-processed for improved functionality (MCC + colloidal silicon dioxide, lactose + MCC combinations).
• Excipients designed for continuous manufacturing processes (as opposed to batch processes).
• Biodegradable and biopolymer-based excipients for injectable and implantable drug delivery.
• Excipients for novel dosage forms: transdermal patches, dissolving microneedles, inhaled powder formulations.

Frequently Asked Questions

What are pharmaceutical excipients?

The inactive ingredients in a drug product — everything other than the active pharmaceutical ingredient. They include fillers, binders, coatings, lubricants, preservatives and stabilisers that make the drug manufacturable, stable, safe and effective as delivered.

Why do tablets need so many excipients?

APIs alone are often present in tiny amounts and cannot form a stable, compressible tablet without bulking agents (fillers), binding agents, disintegrants to ensure dissolution and lubricants to enable tabletting machinery to function. Each excipient serves a specific technical function.

What is an enteric coating?

A polymer coating (often acrylic acid copolymers) that resists dissolution in the acidic stomach environment but dissolves in the neutral small intestine. Used to protect drugs degraded by stomach acid (like proton pump inhibitors) or to protect the stomach from irritating drugs.

Are excipients safe?

Yes — pharmaceutical excipients have well-established safety profiles with defined acceptable daily intake limits. They are tested for safety and quality under pharmacopoeial standards. However, some patients have sensitivities or allergies to specific excipients (lactose intolerance, PEG allergy), which must be considered in prescribing.

Excipient Safety and Quality Systems

Pharmaceutical excipient manufacturers increasingly operate under pharmaceutical quality management systems — Good Manufacturing Practice (GMP) or equivalent — to support drug manufacturers' regulatory submissions. The IPEC-PQG GMP Guide for excipients provides a framework for quality management that, while voluntary, is increasingly expected by major pharmaceutical customers. Excipient audits by pharmaceutical companies are routine, particularly for new suppliers. Pharmacopoeial compliance (USP, EP, JP) provides a baseline quality standard, but many pharmaceutical customers require additional specifications beyond pharmacopoeia minima for critical quality attributes such as particle size distribution, polymorphic form or impurity profiles. For drug delivery technology context, see our guide to the drug delivery systems market.

The increasing share of complex generic drugs — solid dispersions, modified release systems, lipid-based formulations — is expanding excipient technology requirements beyond commodity fillers. Amorphous solid dispersions (hot melt extrusion, spray drying) require specialised polymers (HPMC-AS, PVP-VA, Kollidon VA64) with tightly controlled molecular weight and moisture content. These technical excipients command premium prices and require close collaboration between excipient suppliers and formulators. Co-processed excipients — physical mixtures of two or more excipients processed together to create improved functionality — are growing as drug developers seek direct compression formulations with better flow and compressibility characteristics. The excipient innovation pipeline closely tracks the drug pipeline: as new drug modalities (RNA therapeutics, cell and gene therapy, oral biologics) advance, they create needs for entirely new classes of excipients.

Conclusion

Pharmaceutical excipients are the unsung heroes of drug formulation — enabling drugs to be manufactured, stabilised, delivered and absorbed effectively. As drugs become more complex, excipient innovation is increasingly important. Contact Actual Market Research for detailed analysis of pharmaceutical excipients and drug formulation market segments.